Progresívna multifokálna leukoencefalopatia spojená s rituximabom

English version

Autoři: Juraj Sokol ¹; Lenka Lisá ¹; Jana Zeleňáková ²; Tomáš Balhárek ³; Ivana Plameňová ¹; Ján Staško ¹; Peter; Kubisz ¹
Působiště autorů: Department of Haematology and Transfusion Medicine, National Centre of Haemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovakia ¹; Department of Neurology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovakia ²; Department of Pathological Anatomy, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovakia ³
Vyšlo v časopise: Vnitř Lék 2017; 63(1): 60-64
Kategorie: Kazuistika

Souhrn

Progresívna multifokálna leukoencefalopatia (PML) bola prvýkrát popísaná v roku 1958 u pacienta s lymfoproliferatívnym ochorením. V roku 1971 bol izolovaný John Cunninghamov vírus (JCV), ktorý je zodpovedný za vznik tohto ochorenia. V našej práci popisujeme raritný prípad 62-ročného pacienta s chronickou lymfocytovou leukémiou a PML. Zároveň diskutujeme o diagnostických a terapeutických výzvach a ponúkame návrhy prevencie rozvoja PML. Hlavnými závermi práce sú: 1. Potrebný je pravidelný monitoring sérových hladín imunoglobulínov a pomeru CD4⁺ : CD8⁺ T-lymfocytov, podanie intravenóznych imunoglobulínov je potrebné zvážiť pri ich poklese. 2. Pri poklese pomeru CD4⁺ : CD8⁺ T-lymfocytov a nemožnosti podať intravenózne imunoglobulíny musíme zvážiť pokračujúci prínos podávania imunoterapie. 3. Pri objavení sa neurologickej symptomatológie u pacienta, ktorý podstupuje imunosupresívnu liečbu, musí lekár vysloviť podozrenie na možný rozvoj PML.

Kľúčové slová:
JC vírus –⁠ odporúčanie –⁠ progresívna multifokálna leukoencefalopatia –⁠ rituximab

Zdroje

1. Aström KE, Mancall EL, Richardson EP. Progressive multifocal encephalopathy: a hitherto unrecognized complication of chronic lymphocytic leukemia and lymphoma. Brain 1958; 81 : 93–111.

2. Padgett BL, Walker DL, Zu Rhein GM et al. Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet 1971; 1(7712): 1257–1260.

3. Major EO, Amemiya K, Tornatore CS et al. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 1992; 5(1): 49–73.

4. Isella V, Marzorati L, Curto N et al. Primary progressive multifocal leukoencephalopathy: report of a case. Funct Neurol 2005; 20(3): 139–142.

5. Knowles WA, Pipkin P, Andrews N et al. Population-based study of antibody to the human polyomavirusesBKV and JCV and the simian polyomavirus SV40. J Med Virol 2003; 71(1): 115–123.

6. Egli A, Infanti L, Dumoulin A et al. Prevalence of polyomavirus BK and JC infection and replication in 400healthy blood donors. J Infect Dis 2009; 199(6): 837–846.

7. Stolt A, Sasnauskas K, Koskela P et al. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003; 84(Pt 6): 1499–1504.

8. Berger JR, Major EO. Progressive multifocal leukoencephalopathy. Semin Neurol 1999; 19(2): 193–200.

9. Táborský P, Hrabánek J, Matl I et al. Progresivní multifokální leukoencefalopatie u nemocné po transplantaci ledviny. Vnitř Lék 1998; 44(2): 108–110.

10. Tavazzi E, Ferrate P, Khalili K Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin Microbiol Infect 2011; 17(12): 1776–1780. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1469–0691.2011.03653.x>.

11. Koralnik IJ, Wüthrich C, Dang X et al. JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol 2005; 57(4): 576–580.

12. Viallard JF, Ellie E, Lazaro E et al. JC virus meningitis in a patient with systemic lupus erythematosus. Lupus 2005; 14(12): 964–966.

13. Behzad-Behbahani A, Klapper PE, Vallely PJ et al. BKV-DNA and JCV-DNA in CSF of patients with suspected meningitis or encephalitis. Infection 2003; 31(6): 374–378.

14. Blake K, Pillay D, Knowles W et al. JC virus associated meningoencephalitis in an immunocompetent girl. Arch Dis Child 1992; 67(7): 956–957.

15. Fontoura P, Vale J, Lima C et al. Progressive myoclonic ataxia and JC virus encephalitis in an AIDS patient. J Neurol Neurosurg Psychiatry 2003; 72(5): 653–656.

16. Tallantyre EC, Paine SM, Sharp CP et al. Atypical progressive multifocal leukoencephalopathy associated with an unusual JC polyomavirus mutation. Arch Neurol 2009; 66(8): 1021–1024. Dostupné z DOI: <http://dx.doi.org/10.1001/archneurol.2009.94>.

17. Cinque P, Koralnik IJ, Gerevini S et al. Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis 2009; 9(10): 625–636. Dostupné z DOI: <http://dx.doi.org/10.1016/S1473–3099(09)70226–9>.

18. Goldberg SL, Pecora AL, Alter RS et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99(4): 1486–1488.

19. Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports [RADAR] project. Blood 2009; 113(20): 4834–4840. Dostupné z DOI: http://dx.doi.org/10.1182/blood-2008–10–186999.

20. Tuccori M, Focosi D, Blandizzi C et al. Inclusion of rituximab in treatment protocols for non-Hodgkin’s lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist 2010; 15(11): 1214–1219. Dostupné z DOI: http://dx.doi.org/10.1634 theoncologist.2010–0098.

21. Clifford DB, Ances B, Costello C et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011; 68(9): 1156–1164. Dostupné z DOI: http://dx.doi. org/10.1001/archneurol.2011.103.

22. Teramoto T, Kaneko H, Funato M et al. Progressive multifocal leukoencephalopathy in a patient with X-linked agammaglobulinemia. Scand J Infect Dis 2003; 35(11–12): 909–910.